Managed Access Programs for INC424, Ruxolitinib

Status Available

Clinical Trial Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Clinical Trial Description

CINC424A2405 - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424A2405 to provide access to Ruxolitinib for patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) CINC424A2001M - No longer available - Ruxolitinib Managed Access Program (MAP) for patients diagnosed with severe/very severe COVID-19 illness CINC424B2002I - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424B2002I to provide access to Ruxolitinib for patients with Polycythemia Vera (PV) CINC424C2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424C2001M to provide access to ruxolitinib for steroid refractory acute and chronic Graft versus Host Disease (SR aGVHD and SR cGHVD). ;

Study Design

Related Conditions & MeSH terms

Bronchiolitis Obliterans Syndrome
Graft vs Host Disease
Polycythemia
Polycythemia Vera
Polycythemia Vera (PV)
Post Polycythemia Myelofibrosis (PPV MF)
Primary Myelofibrosis
Primary Myelofibrosis (PMF)
Severe/Very Severe COVID-19 Illness
Thrombocythemia Myelofibrosis (PET-MF)
Thrombocytosis

Clinical Trial Details

NCT number	NCT04745637
Study type	Expanded Access
Source	Novartis
Contact	MAP requests are initiated by a licensed physician.https:// www.
Phone	1-88-669-6682
Email	novartis.email@novartis.com
Status	Available
Phase

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03441113` - Extended Access of Momelotinib in Adults With Myelofibrosis	Phase 2
Completed	`NCT01558739` - Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)	Phase 4
Completed	`NCT00910728` - Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases	Phase 1
Completed	`NCT02101268` - Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF	Phase 3
Completed	`NCT03136185` - Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)	Phase 1/Phase 2
Completed	`NCT04217993` - Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis	Phase 2
Completed	`NCT02515630` - Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Phase 2
Recruiting	`NCT03662126` - KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment	Phase 2/Phase 3
Terminated	`NCT03935555` - Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib	Phase 1
Recruiting	`NCT04878003` - Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis	Phase 2